ABIO ARCA biopharma Inc.

5.73
-0.08  -1%
Previous Close 5.81
Open 5.77
Price To Book 1.05
Market Cap 6303000
Shares 1,100,000
Volume 26,649
Short Ratio
Av. Daily Volume 118,374

NewsSee all news

  1. Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
  2. Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
  3. ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
  4. ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
  5. Zosano Appoints Linda Grais M.D., J.D. to Board of Directors

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 4Q 2019 under SPA subject to securing additional financing.
Gencaro
Chronic Heart Failure

Latest News

  1. Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
  2. Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
  3. ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
  4. ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
  5. Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
  6. ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling
  7. ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
  8. ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  9. GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
  10. ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
  11. Westminster biotech company receives second extension on delisting notice from Nasdaq
  12. Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics
  13. Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018
  14. 3 Biotech Stocks in Focus on Tuesday
  15. Today’s Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma
  16. Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks